NZ312502A - Clostridium difficile toxins as mucosal adjuvants - Google Patents

Clostridium difficile toxins as mucosal adjuvants

Info

Publication number
NZ312502A
NZ312502A NZ312502A NZ31250296A NZ312502A NZ 312502 A NZ312502 A NZ 312502A NZ 312502 A NZ312502 A NZ 312502A NZ 31250296 A NZ31250296 A NZ 31250296A NZ 312502 A NZ312502 A NZ 312502A
Authority
NZ
New Zealand
Prior art keywords
clostridium difficile
mucosal adjuvants
difficile toxins
mammal
antigen
Prior art date
Application number
NZ312502A
Other languages
English (en)
Inventor
William D Thomas
Thomas P Monath
Zhenxi Zhang
Francisco Javier Torres-Lopez
Wende Lei
David M Lyerly
James S Moncrieff
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27053134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ312502(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/543,708 external-priority patent/US5919463A/en
Application filed by Oravax Inc filed Critical Oravax Inc
Publication of NZ312502A publication Critical patent/NZ312502A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NZ312502A 1995-07-07 1996-07-01 Clostridium difficile toxins as mucosal adjuvants NZ312502A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49938495A 1995-07-07 1995-07-07
US08/543,708 US5919463A (en) 1995-07-07 1995-10-16 Clostridium difficle toxins as mucosal adjuvants
PCT/US1996/011142 WO1997002836A1 (en) 1995-07-07 1996-07-01 Clostridium difficile toxins as mucosal adjuvants

Publications (1)

Publication Number Publication Date
NZ312502A true NZ312502A (en) 1999-03-29

Family

ID=27053134

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ312502A NZ312502A (en) 1995-07-07 1996-07-01 Clostridium difficile toxins as mucosal adjuvants

Country Status (9)

Country Link
EP (1) EP0837692B1 (https=)
JP (1) JPH11509200A (https=)
CN (1) CN1195297A (https=)
AT (1) ATE195878T1 (https=)
AU (1) AU720567B2 (https=)
CA (1) CA2226339A1 (https=)
DE (1) DE69610106D1 (https=)
NZ (1) NZ312502A (https=)
WO (1) WO1997002836A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
AU746859B2 (en) * 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
EP1568378B1 (en) * 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
EP2305293A3 (en) 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
AU6524798A (en) * 1998-03-31 1999-10-18 Dae Woong Pharmaceutical Co., Ltd. A preventive and therapeutic vaccine for (helicobacter pylori)-associated diseases
JP2002542169A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
WO2000061761A2 (en) * 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP2553102B1 (en) 2010-03-30 2015-12-09 Pfenex Inc. High level expression of recombinant toxin proteins
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
EP2714910B1 (en) * 2011-05-27 2018-01-10 GlaxoSmithKline Biologicals SA Immunogenic composition
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
AU4773293A (en) * 1992-07-16 1994-02-14 Oxford University Multiple particulate antigen delivery system
GB9305919D0 (en) * 1993-03-22 1993-05-12 Health Lab Service Board Botulinum toxin polypeptides and their use as vaccines

Also Published As

Publication number Publication date
ATE195878T1 (de) 2000-09-15
JPH11509200A (ja) 1999-08-17
AU6404796A (en) 1997-02-10
CA2226339A1 (en) 1997-01-30
EP0837692B1 (en) 2000-08-30
CN1195297A (zh) 1998-10-07
DE69610106D1 (de) 2000-10-05
EP0837692A4 (https=) 1998-04-29
AU720567B2 (en) 2000-06-08
EP0837692A1 (en) 1998-04-29
WO1997002836A1 (en) 1997-01-30

Similar Documents

Publication Publication Date Title
NZ312502A (en) Clostridium difficile toxins as mucosal adjuvants
ATE326231T1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
IL107026A0 (en) Antigen of hybrid m protein and carrier for group a streptococcal vaccine
ATE127345T1 (de) Stressproteine und verwendungen dafür.
EP0652758A4 (en) VACCINES AGAINST DIPHTERY TOXIN.
EP1170016A3 (en) Urease-based vaccine against helicobacter infection
TR199801722T2 (xx) Peptit imm�nojenler.
AP2000001886A0 (en) Group B streptococcus antigens.
EP1385541A4 (en) IMMUNOSTIMULATING COMBINATIONS CONTAINING AMINO ALKYL GLUCOSAMINE IDEPHOSPHATE AND QS-21
AU2917697A (en) Dendritic cell receptor
WO1994010317A3 (en) Conjugate vaccine against group b streptococcus
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
ES483374A1 (es) Procedimiento para modificar las propiedades antigenas de unantigeno de polen de la hierba
KR100218138B1 (en) Methods and vaccines comprising surface-active copolymers
WO1999065518A3 (en) Lt and ct in parenteral immunization methods against helicobacter infection
GB9501826D0 (en) Polypeptide fragments
GR3018820T3 (en) Use of il-4 to enhance immune response to immunogens in vaccines.
DE69626642T2 (de) Cetp zur erhöhung des hdl-cholesterol-gehalts
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
NZ333191A (en) Human dendritic cell receptor DEC-205
NO980721L (no) Vaksiner

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)